Role of Ifitm/Fragilis proteins as intracellular shuttles during cell activation
Role of Ifitm/Fragilis proteins as intracellular shuttles during cell activation
批准号:
8043909
负责人:
John Weis
金额:
$22.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2012-11-30
关键词:
AdhesionsAnimalsAutoimmunityB-LymphocytesBindingBiologicalBiological AssayCD81 geneCell ProliferationCell Surface ReceptorsCell membraneCell physiologyCell surfaceCellsCellular MembraneComplexCytoplasmDepressed moodDown-RegulationEnzymesEventFamily memberFutureGoalsHumanImmuneImmune responseInfectionInterferon ActivationInterferon Type IIInterferonsLeadLocationMammalian CellMembraneMembrane MicrodomainsMembrane ProteinsModelingModificationMolecularMovementMusNormal CellPathway interactionsPhagocytesPhenocopyPhenotypePost-Translational Protein ProcessingProductionPropertyProtein BindingProtein KinaseProteinsPublicationsRestRoleSet proteinSignal TransductionSiteSurfaceTestingTissuesUbiquitinViralVirusVirus DiseasesYeastsbasedesignhuman PHEMX proteinmacrophagemanmigrationpreventprotein degradationprotein functionreceptorresearch studyresponserestorationyeast two hybrid system
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The central focus of this project is to test the hypothesis that the Ifitm proteins down-modulate cell activation and prevent viral infections by shuttling modifying enzymes to the cell surface to degrade activation complexes. The activation of cells of the immune response often requires signaling through cell surface receptors. This event brings into activation domains, such as lipid rafts, both the activating proteins (kinases, etc) and the substrates (receptors and intracellular signaling partners). In some cells (phagocytic cells such as macrophages and B cells) many such complexes are internalized and degraded. Other activation complexes on these and other cells, however, remain on the cell surface and require modification to block further cellular activation. The Ifitm proteins have been characterized as functioning to help down-regulate activated cells, depressing adhesion and proliferation. In addition they were recently characterized as the major determinants of the anti-viral state in mammalian cells after activation with type I and type II interferons. However, the mechanism by which the Ifitm proteins accomplish these effects has not been described. We have found that the Ifitm proteins can bind to a variety of proteins whose functions are associated with the modification of proteins by the addition of substrates (such as ubiquitin or SUMO) or enzymatic cleavage. We propose that the Ifitm proteins are held within the cell and are released following activation to intercalate within the membrane. As the Ifitm proteins make this migration, they carry these modifying proteins as cargo for association with proteins within the membrane. The delivery of these cargo proteins into activation complexes is followed by their action to degrade and/or modify surface proteins thus depressing cell activation. This same pathway is also proposed to function to control viral infection. We propose to target one specific cargo protein in particular, Bat5, which has been shown to bind to the Ifitm proteins of man and mouse. We further propose that the absence of this pathway will allow for uninhibited cellular activation potentially leading to increased cell proliferation and lack of immune control that could lead to autoimmunity and tissue damage.
PUBLIC HEALTH RELEVANCE: The control of cell activation requires pathways that down regulate activating complexes and components. The Ifitm proteins have been implicated as helping depress cell activation and enhance innate immune defenses to certain viral infections but no mechanisms as to how they accomplish this have been demonstrated. We propose to test the hypothesis that the Ifitm proteins shuttle cargo enzymes into membrane activation complexes. These enzymes then target constituents of such sites for modification and degradation thus depressing activation and inhibiting infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Ifitm/Fragilis proteins as intracellular shuttles during cell activation
-
批准号:8197848
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2010
-
负责人:John Weis
-
依托单位:
Regulation of CR2/CD21 Expression and Activation
-
批准号:7880369
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2009
-
负责人:John Weis
-
依托单位:
Role of the Fragilis Proteins in the Immune Response
-
批准号:6894009
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2004
-
负责人:John Weis
-
依托单位:
Role of the Fragilis Proteins in the Immune Response
-
批准号:6804271
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2004
-
负责人:John Weis
-
依托单位:
Role of Pactolus in the innate immune response
-
批准号:6631980
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
PACTOLUS AND MAST CELL AND MORROW CELL FUNCTION
-
批准号:2705528
-
项目类别:
-
资助金额:$19.68万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
Role of Pactolus in the innate immune response
-
批准号:6886799
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
Role of Pactolus in the innate immune response
-
批准号:6721189
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
PACTOLUS AND MAST CELL AND MORROW CELL FUNCTION
-
批准号:2887616
-
项目类别:
-
资助金额:$20.27万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
Role of Pactolus in the innate immune response
-
批准号:6510757
-
项目类别:
-
资助金额:$33.75万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
PACTOLUS AND MAST CELL AND MORROW CELL FUNCTION
-
批准号:6170928
-
项目类别:
-
资助金额:$20.88万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
Role of Pactolus in the innate immune response
-
批准号:6400854
-
项目类别:
-
资助金额:$30.38万
-
财政年份:1998
-
负责人:John Weis
-
依托单位:
CHARACTERIZATION OF MAST CELL INTEGRINS
-
批准号:2067907
-
项目类别:
-
资助金额:$12.15万
-
财政年份:1993
-
负责人:John Weis
-
依托单位:
CHARACTERIZATION OF MAST CELL INTEGRINS
-
批准号:3148049
-
项目类别:
-
资助金额:$12.06万
-
财政年份:1993
-
负责人:John Weis
-
依托单位:
CHARACTERIZATION OF MAST CELL INTEGRINS
-
批准号:2067908
-
项目类别:
-
资助金额:$14.27万
-
财政年份:1993
-
负责人:John Weis
-
依托单位:
MOLECULAR CHARACTERIZATION OF CR1 AND RELATED PROTEINS
-
批准号:3136915
-
项目类别:
-
资助金额:$4.01万
-
财政年份:1986
-
负责人:John Weis
-
依托单位:
CHARACTERIZATION OF THE MURINE COMPLEMENT RECEPTORS
-
批准号:3136917
-
项目类别:
-
资助金额:$18.9万
-
财政年份:1986
-
负责人:John Weis
-
依托单位:
MURINE COMPLEMENT RECEPTOR CR2
-
批准号:6149754
-
项目类别:
-
资助金额:$23.92万
-
财政年份:1986
-
负责人:John Weis
-
依托单位:
MURINE COMPLEMENT RECEPTOR CR2
-
批准号:2871484
-
项目类别:
-
资助金额:$23.0万
-
财政年份:1986
-
负责人:John Weis
-
依托单位:
REGULATION OF CR2/CD21 EXPRESSION AND ACTIVATION
-
批准号:6288216
-
项目类别:
-
资助金额:$30.0万
-
财政年份:1986
-
负责人:John Weis
-
依托单位:
海外基金